Briviact (Brivaracetam) Patent Expiration, LOE Window & CMS Spending
Briviact (Brivaracetam) by Ucb: FDA Orange Book core substance LOE 2026-02-21 (last listed 2030-04-09), 7 AB generics, $463.4M 2024 CMS Part D & Medicaid spend, and 20 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Ucb |
| FDA Application & Pathway | N205836 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | 2026-02-21 |
| Last Listed Patent or Exclusivity Date | 2030-04-09 |
| Orange Book Patents (*PED Extensions) | 2 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 7 |
| 2024 CMS Total Public Spend | $463.4M |
| 2024 Medicare Part D Spend | $219.8M |
| 2024 Medicaid Spend | $243.6M |
| Reported Wholesale Price Change (CA SB 17) | 20 WAC filings (max 18.3% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for UCB across sibling Meru public-data platforms.